1. Scrip
  2. >>Business
  3. >>Earnings

Is Bayer Making A Mistake With Monsanto When Pharma Is Its Leading Business?

 
• By Lucie Ellis-Taitt

Second-quarter earnings results have raised questions about Bayer AG's long-term strategy, including over how long the company's pharma unit can continue to come out on top and drive the group based on the performance of just five "recently" marketed drugs.

SC1607_Wooden-Figures_1200x675

On the back of mixed second-quarter results it would seem Bayer AG needs to readdress its business priorities: perhaps to focus on further growth of its strong innovative Pharma unit through creative partnerships and in-house R&D investment, instead of conducting massive acquisitions in its failing CropScience and struggling Consumer Health units.

For yet another quarter Bayer's Pharma unit has driven profits and growth for the whole company, while its Consumer Health...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Cidara’s Fortunes Improve Quickly With Non-Vaccine Flu-Prevention Data

 
• By Joseph Haas

Having recently abandoned the antifungal space, Cidara’s stock soared on Phase IIb data showing that its drug-Fc conjugate prevents seasonal flu at rates from 57%-76%.

Novo And Lilly Lay Out Patient Segmentation Plans For Obesity Treatment

 
• By Andrew McConaghie

As competition heats up and the obesity market matures, the two frontrunners are tailoring their studies to the wants and needs of different patient groups.

Vertex Heralds ‘Unprecedented’ Zimislecel Type 1 Diabetes Data

 
• By Kevin Grogan

The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.